-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The monitoring of chronic myeloid leukemia is usually achieved by PCR technology
The pathogenic basis of chronic myeloid leukemia (CML) is the translocation of c-ABL located on 9q34 to the 3'end of the BCR gene on 22q11, forming a BCR-ABL fusion gene
Today, the clinical cut-off point of BCR-ABL transcript level is MR3.
Many patients have remained below MR3.
According to Patel, since the introduction of digital PCR in Bio-Rad in 2011, multiple research teams have developed alternative methods for measuring the level of BCR-ABL transcripts using ddPCR
ddPCR can detect rare nucleic acid mutations in the complex background of wild-type (normal) molecular mixtures
Patel believes that the sensitivity and accuracy of ddPCR can help doctors understand the small changes in BCR-ABL transcript levels over time
Currently, Bio-Rad's QXDx BCR-ABL%IS Test has passed CE-IVD certification in Europe
In addition, due to its ability to detect rare variants, digital PCR technology is being used in a wide range of clinical applications, including oncology testing, transplant monitoring, infectious diseases, and prenatal/newborn screening
Looking to the future, Patel said: "In the next 10-20 years, I believe we will be able to obtain more information from the human genome and begin to transform it into medicines and diagnostics
